Genetics Institute, Inc.

Novartis Corporation

Other

Ludwig Institute for Cancer Research Limited

Wyeth

The Wistar Institute

Aveo Pharmaceuticals, Inc.

Steven C. Clark

Agnes B. Ciarletta

Yu-chung Yang

Robert E. Donahue

Susan T. Ricciardi

Steven C Clark

Gordon G Wong

Rodney M Hewick

Giorgio Trinchieri

Bice Perussia

Michiko Kobayashi

Yu-Chung Yang

Agnes B Ciarletta

Randal J Kaufman

Stanley F Wolf

Katherine Jane Turner

Thomas G Gesner

Kenneth A Jacobs

Robert E Donahue

Susan T Ricciardi

Elizabeth A Wang

Paul F Schendel

David A Williams

John M McCoy

John R McCoy

Tyler E Jacks

Murray Robinson

Ronan O'Hagan

Yinghui Zhou

Joerg Heyer

Ronald A Depinho

William Rideout, Iii

Gordon C Wong

Ronald Depinho

William Iii Rideout

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.

Chimeric cancer models

Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.

Megakaryocyte stimulating factors

This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.

Natural killer stimulatory factor

Antibodies to natural killer stimulatory factor

Novel human megakaryocyte stimulating factors (MSFS) capable of stimulating the growth and development of colonies of megakaryocytes, pharmaceutical compositions containing same, and methods for their preparation and use are provided.

IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other hematopoietins in cancer therapies.

Production and use of IL-6

Antibodies reactive with a novel homogeneous human cytokine, Natural Killer Stimulatory Factor, (NKSF), NKSF having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing such antibodies.

Methods of treatment using IL-6

A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises: preparing RNA from a cell that produces CSF; preparing polyadenylated messenger RNA from said RNA; preparing single stranded cDNA from said messenger RNA; converting the single stranded cDNA to double stranded cDNA; inserting the double stranded cDNA into transformation vectors and transforming bacteria with said vector to form colonies; picking pools of 200 to 500 colonies each and isolating plasmid DNA from each pool; transfecting the plasmid DNA into suitable host cells for expressing CSF protein; culturing the transfected cells and assaying the supernatant for CSF activity; and selecting CSF positive pools and screening the colonies used to make the pool to identify a colony having CSF activity. Also described are a cDNA coding for a protein having CSF activity (i.e. CSF/cDNA), a microorganism or cell line transformed with a recombinant vector containing such CSF/cDNA, and a method for producing CSF protein by expressing said CSF/cDNA by culturing a microorganism or cell line.

Recombinant primate granulocyte macrophage-colony stimulating factor

A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises:

DNA encoding GM-CSF and a method of producing GM-CSF protein

Recombinant human granulocyte-macrophage-colony stimulating factor

A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.

This invention provides a novel human erythropoietic growth factor and processes for producing it by recombinant DNA genetic engineering techniques.

DNA encoding the human cytokine, interleukin-9

Method of treating myelo-suppression with GM-CSF

Growing community of inventors

Winchester, MA, United States of America

Steven C Clark